Markers defining immune subsets (CD3, CD4, CD8, Foxp3, CD68, and CD163) were stained for the patients' paired tumor samples, as described in Table S2 and Figures S1 A–F, and a comparison was performed based on IDH1 mutation status (only the IDH1-specific antibody was available) (Figures 2A,B). Here, CD163 is linked to neoplasm.